Network Insights Methodology Whitepaper Get Access

Eli Lilly

PERSON Health Care / Pharmaceuticals Momentum 6.5ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. HIGHPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$34.1B revenue (2025), Indianapolis-based Eli Lilly manufactures diabetes, obesity, and immunology drugs including Mounjaro and Tirzepatide. Selected for FDA's PreCheck pilot and facing Congressional pressure to expand 340B hospital discount program participation.

Selected for FDA's PreCheck pilot program; subject to legislative pressure regarding 340B drug discount program participation
2.07
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
6.5
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
43
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Eli Lilly is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
NYSE Morgan Stanley FDA PlocamiumAI Novo Nordisk China Merck AstraZeneca HHS Washington Nvidia Apple Americans M&A Alphabet
Watch This Entity
PSI Intelligence
30-Day Trend
2026-06-08 2026-07-08 43 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.293
Spectral Shift
533.141
Sentiment-Momentum Divergence
0.000
Source Concentration
0.233
Signal
Eli Lilly is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #1 of 79 in Health Care — sector outlier (4.3 sigma above median). PSI up 0.62 from yesterday (1.45 -> 2.07).
Action
Significant regime shift. Immediate review recommended. Check for pending announcements, regulatory actions, or deal activity.
Peer Comparison
1 of 79
Sector Rank
+4.26
Peer Z-Score
100%
Sector Percentile
Network Analysis
43 Degree Centrality
Ego Network (top connections)
NYSE (weight 24.0)Morgan Stanley (weight 18.0)FDA (weight 18.0)PlocamiumAI (weight 16.0)Novo Nordisk (weight 16.0)China (weight 13.0)Merck (weight 12.0)AstraZeneca (weight 8.0) NYSEMorgan StanleyFDAPlocamiumAINovo NordiskChinaMerckAstraZeneca Eli Lilly (degree 43) Eli Lilly
Centrality History
2026-06-08 2026-07-08 43 0 Degree Mentions
EntityWeight StatusFirst Seen
NYSE 24 NEW
Morgan Stanley 18 NEW
FDA 18 NEW
PlocamiumAI 16 NEW
Novo Nordisk 16 NEW
China 13 NEW
Merck 12 NEW
AstraZeneca 8 NEW
HHS 8 NEW
Washington 7 NEW
Nvidia 7 NEW
Apple 6 NEW
Americans 6 NEW
M&A 5 NEW
Alphabet 5 NEW
United States 5 NEW
CEO 4 NEW
Europe 4 NEW
Reuters 4 NEW
Amazon 4 NEW
Microsoft 4 NEW
Walmart 4 NEW
Wall Street 4 NEW
Bloomberg 4 NEW
Beijing 3 NEW
Novartis 3 NEW
Hong Kong 3 NEW
Berkshire Hathaway 3 NEW
Broadcom 3 NEW
Elon Musk 3 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-07-08 ← Intelligence Network